Filing Details

Accession Number:
0001349929-17-000067
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2017-08-18 16:32:37
Reporting Period:
2017-08-17
Filing Date:
2017-08-18
Accepted Time:
2017-08-18 16:32:37
Original Submission Date:
2017-08-18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1349929 Cancer Genetics Inc CGIX () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
897464 John Pappajohn 201 Route 17 North
2Nd Floor
Rutherford NJ 07070
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2017-08-17 66,185 $3.24 2,608,704 No 4 P Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2017-08-18 20,000 $3.28 2,628,704 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.15 to $3.30, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. The original Form 4, filed on August 18, 2017 is amended to correctly reflect the transaction date. No other changes have been made to the original Form 4.
  3. 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.30, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.